tbuckley/cabot-search huggingface dataset:
Natural History and Intervention Thresholds for Ascending Thoracic Aortic Aneurysm—Not an Easy Nut to Crack
Authors: Mohammad A. Zafar, John A. Elefteriades
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Correction: Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer
Authors: Fernando Salvador, Alberto Martin, Celia López-Menéndez, Gema Moreno-Bueno, Vanesa Santos, Alberto Vázquez-Naharro, Patricia G. Santamaría, Saleta Morales, Pierre R. Dubus, Laura Muinelo-Romay, Rafael López-López, Jason C. Tung, Valerie M. Weaver, Francisco Portillo, Amparo Cano
Journal: Cancer Research (2023)

In the original version of this article (1), there were errors in Fig. 2 and Fig. 7. Specifically, in Fig. 2, the hematoxylin and eosin images of the metastatic lung in Fig. 2A for the knockout PyMT;LΔ/− mice and the metastatic lung in Fig. 2C for the control PyMT;R26STOPL2 mice were both mistakenly taken from the same original image. In Fig. 7A, the same Western blot bands were used to represent α-tubulin expression in the T1 control samples and Snail 1 expression in the T1 Snail1 samples. In addition, the orientation of the Snail 1 Western blot bands in the T2 Snail1 samples was incorrect in the original version. The correct images have been provided and the errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.
Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis
Authors: Michael Willmann, Barbara Peter, Katharina Slavnitsch, Daniela Berger, Nadine Witzeneder, Gabriele Stefanzl, Gregor Eisenwort, Daniel Ivanov, Irina Sadovnik, Emir Hadzijusufovic, Georg Greiner, Tina Bernthaler, Gregor Hoermann, Maik Dahlhoff, Thomas Rülicke, Peter Valent
Journal: Leukemia (2023)

Systemic mastocytosis (SM) is a heterogeneous group of disorders characterized by abnormal growth and accumulation of mast cells (MC) in various organ-systems [1][2][3].The classification of the World Health Organization (WHO) divides SM into non-advanced forms and advanced forms of the disease.Whereas patients with non-advanced SM, such as indolent SM (ISM) or smoldering SM (SSM) have an excellent prognosis, the prognosis and survival of patients with advanced SM, including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and MC leukemia (MCL), are dismal [1][2][3].Despite the prognostic value of the WHO classification, availability of additional prognostic variables, and recently developed prognostic scores, it is often difficult to predict the course and prognosis in individual patients [4,5].For example, even patients with ISM who have no or only a few risk factors concerning progression, may sometimes progress to ASM or MCL.One strategy to define the expansion and progression of neoplastic cells may be to measure the dynamics of MC-related parameters such as the tryptase level or MC infiltration grade in the bone marrow (BM) [6,7].However, serum tryptase levels may also increase in ISM or SSM without signs of progression and serial BM investigations are usually not performed.It is also difficult to measure the proliferative capacity of neoplastic progenitors in patients with SM [8].Another approach may be to measure the numbers and disease-propagating ability of neoplastic stem cells in patients with SM.However, the lack of suitable in vivo models reflecting non-advanced SM and advanced SM has limited previous attempts to correlate in vivo expansion of SM cells with clinical endpoints and prognosis.The concept of leukemic stem cells (LSC) is well established in acute and chronic leukemias [9,10].More recently, we have identified LSC in patients with advanced SM, including MCL [11].In most patients with MCL, LSC were found to produce detectable engraftment in NSG mice exhibiting membrane-bound human stem cell factor (NSG SCF ) [11].We also found that engraftment
Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants
Authors: Ogo Egbuna, Brandon Zimmerman, George Manos, Anne Fortier, Madalina C. Chirieac, Leslie A. Dakin, David J. Friedman, Kate Bramham, Kirk Campbell, Bertrand Knebelmann, Laura Barisoni, Ronald J. Falk, Debbie S. Gipson, Michael S. Lipkowitz, Akinlolu Ojo, Mark E. Bunnage, Martin R. Pollak, David Altshuler, Glenn M. Chertow
Journal: New England Journal of Medicine (2023)

Persons with toxic gain-of-function variants in the gene encoding apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive, proteinuric nephropathy. Despite the known genetic cause, therapies targeting proteinuric kidney disease in persons with two APOL1 variants (G1 or G2) are lacking. Download a PDF of the Research Summary. We used tetracycline-inducible APOL1 human embryonic kidney (HEK293) cells to assess the ability of a small-molecule compound, inaxaplin, to inhibit APOL1 channel function. An APOL1 G2–homologous transgenic mouse model of proteinuric kidney disease was used to assess inaxaplin treatment for proteinuria. We then conducted a single-group, open-label, phase 2a clinical study in which inaxaplin was administered to participants who had two APOL1 variants, biopsy-proven focal segmental glomerulosclerosis, and proteinuria (urinary protein-to-creatinine ratio of ≥0.7 to <10 [with protein and creatinine both measured in grams] and an estimated glomerular filtration rate of ≥27 ml per minute per 1.73 m2 of body-surface area). Participants received inaxaplin daily for 13 weeks (15 mg for 2 weeks and 45 mg for 11 weeks) along with standard care. The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants who had at least 80% adherence to inaxaplin therapy. Safety was also assessed. In preclinical studies, inaxaplin selectively inhibited APOL1 channel function in vitro and reduced proteinuria in the mouse model. Sixteen participants were enrolled in the phase 2a study. Among the 13 participants who were treated with inaxaplin and met the adherence threshold, the mean change from the baseline urinary protein-to-creatinine ratio at week 13 was −47.6% (95% confidence interval, −60.0 to −31.3). In an analysis that included all the participants regardless of adherence to inaxaplin therapy, reductions similar to those in the primary analysis were observed in all but 1 participant. Adverse events were mild or moderate in severity; none led to study discontinuation. Targeted inhibition of APOL1 channel function with inaxaplin reduced proteinuria in participants with two APOL1 variants and focal segmental glomerulosclerosis. (Funded by Vertex Pharmaceuticals; VX19-147-101 ClinicalTrials.gov number, NCT04340362.) QUICK TAKE VIDEO SUMMARYInaxaplin for Proteinuric Kidney Disease with High-Risk APOL1 Variants 02:06
Malignant Acanthosis Nigricans
Authors: Huei-Jing Wang, S Chu-Sung Hu
Journal: New England Journal of Medicine (2023)

A 30-year-old woman presented with a 3-month history of hyperpigmented, papillomatous, and velvety plaques and papules on her face, axillae, and groin. She also reported unintentional weight loss.
IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
Authors: Keitaro Fukuda
Journal: The Journal of Experimental Medicine (2023)

In this issue of JEM, Reijers et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20221952) demonstrate that pre- and post-treatment IFNγ-related gene expression scores are promising markers for choosing neoadjuvant immunotherapy for stage III melanoma.
Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study
Authors: Jonathan S Zipursky, Tara Gomes, Karl Everett, Andrew Calzavara, J Michael Paterson, Peter C Austin, Muhammad M Mamdani, Joel G Ray, David N Juurlink
Journal: BMJ (2023)

Abstract Objective To examine whether maternal opioid treatment after delivery is associated with an increased risk of adverse infant outcomes. Design Population based cohort study. Setting Ontario, Canada. Participants 865 691 mother-infant pairs discharged from hospital alive within seven days of delivery from 1 September 2012 to 31 March 2020. Each mother who filled an opioid prescription within seven days of discharge was propensity score matched to a mother who did not. Main outcome measures The primary outcome was hospital readmission of infants for any reason within 30 days of their mother filling an opioid prescription (index date). Infant related secondary outcomes were any emergency department visit, hospital admission for all cause injury, admission to a neonatal intensive care unit, admission with resuscitation or assisted ventilation, and all cause death. Results 85 675 mothers (99.8% of the 85 852 mothers prescribed an opioid) who filled an opioid prescription within seven days of discharge after delivery were propensity score matched to 85 675 mothers who did not. Of the infants admitted to hospital within 30 days, 2962 (3.5%) were born to mothers who filled an opioid prescription compared with 3038 (3.5%) born to mothers who did not. Infants of mothers who were prescribed an opioid were no more likely to be admitted to hospital for any reason than infants of mothers who were not prescribed an opioid (hazard ratio 0.98, 95% confidence interval 0.93 to 1.03) and marginally more likely to be taken to an emergency department in the subsequent 30 days (1.04, 1.01 to 1.08), but no differences were found for any other adverse infant outcomes and there were no infant deaths. Conclusions Findings from this study suggest no association between maternal opioid prescription after delivery and adverse infant outcomes, including death.
Management of suicide risk in mental health practice
Authors: Zaffer Iqbal
Journal: The Lancet Psychiatry (2023)

In their Personal View in The Lancet Psychiatry Article, Keith Hawton and colleagues1 describe a well thought through approach to suicide risk. The authors postulate not only how suicide prediction measures are ineffective, but also how assessment and formulation of suicide risk allows for an explicit and systematic approach. Hawton and colleagues outline essential steps to reduce suicidal ideation. These steps are clearly and effectively addressed by the Collaborative Assessment and Management of Suicidality (CAMS) Framework and its guiding clinical tool, the Suicide Status Form, which is a comprehensive medical record and multipurpose roadmap for guiding the assessment, stabilisation-planning, and suicide-focused treatment of patients, with additional documentation for all interim care through to disposition.
Flashback Foreword: Activity of First-Line Trastuzumab
Authors: Jennifer J. Griggs
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. March 15, 2023 JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002). March 15, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02843 Journal of Clinical Oncology - published online before print March 15, 2023 PMID: 36921334 Flashback Foreword: Activity of First-Line Trastuzumab Jennifer J. Griggs, MD, MPH1xJennifer J. GriggsSearch for articles by this author Show More 1Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02843 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2002, Vogel et al1 demonstrated that single-agent trastuzumab in people with human epidermal growth factor receptor 2–positive metastatic breast cancer yielded a response rate rivaling chemotherapy and a nonprogression rate of more than 50% at 12 months in people who had declined chemotherapy as first-line therapy. The effect of this trial was the demonstration of activity of single-agent trastuzumab in people with breast cancer who decline chemotherapy and to further illustrate the predictive importance of high levels of overexpression and overamplification of human epidermal growth factor receptor 2.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Activity of First-Line TrastuzumabThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jennifer J. GriggsEmployment: Anglona CorporationStock and Other Ownership Interests: Anglona CorporationNo other potential conflicts of interest were reported. Companion Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer
Authors: Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Journal: Journal of Clinical Oncology (2023)

To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with
3D Bioprinting in Otolaryngology: A Review
Authors: Alexandra McMillan, Nadia McMillan, Nikesh Gupta, Sohit P. Kanotra, Aliasger K. Salem
Journal: Advanced Healthcare Materials (2023)

The evolution of tissue engineering and 3D bioprinting has allowed for increased opportunities to generate musculoskeletal tissue grafts that can enhance functional and aesthetic outcomes in otolaryngology-head and neck surgery. Despite literature reporting successes in the fabrication of cartilage and bone scaffolds for applications in the head and neck, the full potential of this technology has yet to be realized. Otolaryngology as a field has always been at the forefront of new advancements and technology and is well poised to spearhead clinical application of these engineered tissues. In this review, current 3D bioprinting methods are described and an overview of potential cell types, bioinks, and bioactive factors available for musculoskeletal engineering using this technology is presented. The otologic, nasal, tracheal, and craniofacial bone applications of 3D bioprinting with a focus on engineered graft implantation in animal models to highlight the status of functional outcomes in vivo; a necessary step to future clinical translation are reviewed. Continued multidisciplinary efforts between material chemistry, biological sciences, and otolaryngologists will play a key role in the translation of engineered, 3D bioprinted constructs for head and neck surgery.
Tissue-specific macrophages: how they develop and choreograph tissue biology
Authors: Elvira Mass, Falk Nimmerjahn, Katrin Kierdorf, Andreas Schlitzer
Journal: Nature reviews. Immunology (2023)

Macrophages are innate immune cells that form a 3D network in all our tissues, where they phagocytose dying cells and cell debris, immune complexes, bacteria and other waste products. Simultaneously, they produce growth factors and signalling molecules — such activities not only promote host protection in response to invading microorganisms but are also crucial for organ development and homeostasis. There is mounting evidence of macrophages orchestrating fundamental physiological processes, such as blood vessel formation, adipogenesis, metabolism and central and peripheral neuronal function. In parallel, novel methodologies have led to the characterization of tissue-specific macrophages, with distinct subpopulations of these cells showing different developmental trajectories, transcriptional programmes and life cycles. Here, we summarize our growing knowledge of macrophage diversity and how macrophage subsets orchestrate tissue development and function. We further interrelate macrophage ontogeny with their core functions across tissues, that is, the signalling events within the macrophage niche that may control organ functionality during development, homeostasis and ageing. Finally, we highlight the open questions that will need to be addressed by future studies to better understand the tissue-specific functions of distinct macrophage subsets. Macrophages are important for host immunity to infections and for clearing waste products from tissues, but they also maintain tissue health by regulating metabolism, neuronal functions and many other biological processes. Here, Elvira Mass and co-workers discuss the different tissue-specific macrophage populations that are found throughout the body, highlighting shared and unique aspects of their developmental trajectories, transcriptional programmes and physiological functions.
Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial
Authors: Jennifer I. Vidrine, Steven K. Sutton, David W. Wetter, Ya-Chen Tina Shih, Lois M. Ramondetta, Linda S. Elting, Joan L. Walker, Katie M. Smith, Summer G. Frank-Pearce, Yisheng Li, Sarah R. Jones, Darla E. Kendzor, Vani N. Simmons, Damon J. Vidrine
Journal: Journal of Clinical Oncology (2023)

Women who smoke and have a history of cervical intraepithelial neoplasia (CIN) or cervical cancer represent a vulnerable subgroup at elevated risk for recurrence, poorer cancer treatment outcomes, and decreased quality of life. The purpose of this study was to evaluate the long-term efficacy of Motivation And Problem Solving (MAPS), a novel treatment well-suited to meeting the smoking cessation needs of this population.
Lung Cryobiopsy Versus Surgical Lung Biopsy for Diagnosing Fibrotic Interstitial Lung Disease: Still Looking for the “Perfect” Trial
Authors: Rocco Trisolini
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Lung Cryobiopsy versus Surgical Lung Biopsy for Diagnosing Fibrotic Interstitial Lung Disease: Still Looking for the “Perfect” Trial." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. –
Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 Patients
Authors: Yi-Hui Zhou, Paul J. Gallins, Rhonda G. Pace, Hong Dang, Melis A. Aksit, Elizabeth E. Blue, Kati J. Buckingham, Joseph M. Collaco, Anna V. Faino, William W. Gordon, Kurt N. Hetrick, Hua Ling, Weifang Liu, Frankline M. Onchiri, Kymberleigh Pagel, Elizabeth W. Pugh, Karen S. Raraigh, Margaret Rosenfeld, Quan Sun, Jia Wen, Yun Li, Harriet Corvol, Lisa J. Strug, Michael J. Bamshad, Scott M. Blackman, Garry R. Cutting, Ronald L. Gibson, Wanda K. O’Neal, Fred A. Wright, Michael R. Knowles
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Rationale: Lung disease is the major cause of morbidity and mortality in persons with cystic fibrosis (pwCF). Variability in CF lung disease has substantial non-CFTR genetic influence. Identification of genetic modifiers has prognostic and therapeutic importance. Objectives: Identify genetic modifier loci and genes/pathways associated with pulmonary disease severity. Methods: Whole genome sequencing (WGS) data on 4,248 unique pwCF with pancreatic insufficiency (PI) and lung function measures were combined with imputed genotypes from an additional 3,592 PI patients from the US, Canada, and France. This report describes association of ~15.9 million single nucleotide polymorphisms (SNPs), using the quantitative Kulich Normal Residual Mortality Adjusted (KNoRMA) lung disease phenotype in 7,840 pwCF using pre-modulator lung function data. Measurements and Main Results: Testing included common and rare SNPs, transcriptome-wide association, gene level, and pathway analyses. Pathway analyses identified novel associations with genes that have key roles in organ development, and we hypothesize these genes may relate to dysanapsis and/or variability in lung repair. Results confirmed and extended previous GWAS findings. These WGS data provide finely mapped genetic information to support mechanistic studies. No novel primary associations with common single variants or with rare variants were found. Multi-locus effects at chr5p13 (SLC9A3/CEP72) and chr11p13 (EHF/APIP) were identified. Variant effect size estimates at associated loci were consistently ordered across the cohorts, indicating possible age or birth cohort effects. Conclusions: This pre-modulator genomic, transcriptomic, and pathway association study of 7,840 pwCF will facilitate mechanistic and post-modulator genetic studies and, development of novel therapeutics for CF lung disease.